ALUR Stock Overview Focuses on ending obesity with a weight loss platform to treat people who are overweight. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Allurion Technologies Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Allurion Technologies Historical stock prices Current Share Price US$2.93 52 Week High US$98.75 52 Week Low US$2.37 Beta -0.66 1 Month Change -66.32% 3 Month Change -84.21% 1 Year Change -96.08% 3 Year Change -98.29% 5 Year Change n/a Change since IPO -98.30%
Recent News & Updates Allurion Technologies Inc. announced that it expects to receive $2.5 million in funding from RTW Investments, LP Jan 15
New major risk - Market cap size Jan 14
Allurion Technologies Inc. Reaffirms Revenue Guidance for Fourth Quarter and Full Year 2024 Jan 14
Allurion Announces Positive Topline Results From AUDACITY Trial Jan 09 Allurion Technologies Inc. Appoints R. Jason Richey to the Board as A Class II Director Jan 07
Allurion Technologies Inc. has filed a Follow-on Equity Offering in the amount of $30 million. Dec 10
See more updates Allurion Technologies Inc. announced that it expects to receive $2.5 million in funding from RTW Investments, LP Jan 15
New major risk - Market cap size Jan 14
Allurion Technologies Inc. Reaffirms Revenue Guidance for Fourth Quarter and Full Year 2024 Jan 14
Allurion Announces Positive Topline Results From AUDACITY Trial Jan 09 Allurion Technologies Inc. Appoints R. Jason Richey to the Board as A Class II Director Jan 07
Allurion Technologies Inc. has filed a Follow-on Equity Offering in the amount of $30 million. Dec 10
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance Dec 03
Allurion Launches in the US with Its First AI-Native Compounded GLP-1 Program Nov 26
New major risk - Shareholder dilution Nov 25
Consensus revenue estimates decrease by 20%, EPS upgraded Nov 20
Take Care Before Jumping Onto Allurion Technologies Inc. (NYSE:ALUR) Even Though It's 42% Cheaper Nov 15
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 14
Allurion Technologies Inc. Updates Revenue Guidance for the Full-Year 2024 Nov 13
Allurion Technologies Inc. to Report Q3, 2024 Results on Nov 13, 2024 Oct 30 Allurion Technologies Inc., Annual General Meeting, Dec 11, 2024 Oct 29
Allurion Technologies, Inc. Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon Oct 25
Allurion Technologies Receives Written Notice from the New York Stock Exchange Due to Non-Compliance with the Section 802.01B of the NYSE’s Listed Company Manual Sep 06
Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity Sep 05
Allurion Technologies Inc. Announces the Appointment of Keith Johns to Its Board of Directors Sep 03
Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Continued Weight Loss at One Year on the Allurion Program Aug 28
Allurion Technologies Inc. Appoints Adrian Wild as Senior Vice President, International Commercial Aug 20 Allurion Receives Continued Listing Standards Notice from NYSE Aug 16
Allurion Technologies Inc. Updates Earnings Guidance for the Full Year 2024 Aug 14
Allurion Technologies Inc. to Report Q2, 2024 Results on Aug 13, 2024 Jul 17
New major risk - Shareholder dilution Jun 30 Allurion Technologies Inc. has completed a Follow-on Equity Offering in the amount of $17.28781 million. Jun 29
Allurion Technologies Inc. has filed a Follow-on Equity Offering. Allurion Technologies Inc. has filed a Follow-on Equity Offering. Jun 26
Allurion Technologies Inc. Appoints Ojas A. Buch as Chief Operating Officer Jun 06
Allurion Technologies, Inc. Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s May 31
First quarter 2024 earnings released: EPS: US$0.12 (vs US$1.70 loss in 1Q 2023) May 16
Allurion Technologies Inc. Reiterates Revenue Guidance for the Year 2024 May 15
Allurion Technologies Inc. to Report Q1, 2024 Results on May 14, 2024 May 01
Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the First Quarter 2024 Apr 30 Allurion Technologies Inc. announced that it has received $48 million in funding from RTW Investments, LP Apr 19
Allurion Technologies Inc. announced that it has received $48 million in funding from RTW Investments, LP Apr 18
Allurion Technologies, Inc. Expands Virtual Care Suite to the United States Apr 04
Allurion Technologies Inc. Reiterates Earnings Guidance for the Full Year 2024 Mar 23
Full year 2023 earnings released: US$2.27 loss per share (vs US$1.51 loss in FY 2022) Mar 22
New minor risk - Market cap size Mar 21
New minor risk - Share price stability Mar 19
Allurion Technologies Inc. Appoints Milena Alberti-Perez as Board of Directors as Audit Committee Chair Mar 12
Allurion Technologies Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 05
New minor risk - Shareholder dilution Feb 10 Allurion Technologies Inc. Appoints Brendan Gibbons as Its New Chief Legal Officer and Corporate Secretary Jan 29
Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2023 and Full Year of 2024 Jan 10
Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2023 and Full Year of 2024 Jan 09
Allurion Technologies Inc. Announces New Research Highlights the Positive Impact of GLP-1s and Other Anti-Obesity Medications on the Allurion Program Jan 06
Third quarter 2023 earnings released Nov 15 Allurion Technologies Inc. to Report Q3, 2024 Results on Nov 13, 2023 Nov 07
Allurion Technologies, Inc. Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon Oct 12
Second quarter 2023 earnings released Aug 18
No independent directors Aug 04
Allurion Technologies Inc. completed the acquisition of Compute Health Acquisition Corp. (NYSE:CPUH) from Compute Health Sponsor LLC and other in a reverse merger transaction. Aug 03 Shareholder Returns ALUR US Consumer Services US Market 7D -1.3% 4.4% 3.2% 1Y -96.1% 14.5% 24.2%
See full shareholder returns
Return vs Market: ALUR underperformed the US Market which returned 24.2% over the past year.
Price Volatility Is ALUR's price volatile compared to industry and market? ALUR volatility ALUR Average Weekly Movement 24.9% Consumer Services Industry Average Movement 8.2% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ALUR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALUR's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Show more Allurion Technologies Inc. Fundamentals Summary How do Allurion Technologies's earnings and revenue compare to its market cap? ALUR fundamental statistics Market cap US$9.25m Earnings (TTM ) -US$24.76m Revenue (TTM ) US$34.75m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALUR income statement (TTM ) Revenue US$34.75m Cost of Revenue US$9.35m Gross Profit US$25.40m Other Expenses US$50.16m Earnings -US$24.76m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -7.85 Gross Margin 73.09% Net Profit Margin -71.24% Debt/Equity Ratio -116.9%
How did ALUR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 17:25 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Allurion Technologies Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Keay Nakae Chardan Capital Markets, LLC Michael Toomey Jefferies LLC Matthew Taylor Jefferies LLC
Show 2 more analysts 
